United States · Health Care · USD · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD; stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for CNS Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -296.3% | 464.99% | 82.14% | 45.11% | 31.13% | 23.86% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -182.99% | -315.99% | - | - | - | - |
| Total Assets | $8,623,466.00 | $1,422,452.00 | $1,422,452.00 | $1,422,452.00 | $1,422,452.00 | $1,422,452.00 |
| Sector average | $3,280,499,225.95 | $3,298,345,309.75 | $3,676,894,011.56 | |||
| Net Income | -$15,850,564.00 | -$15,871,929.67 | -$15,818,751.03 | -$15,825,421.77 | -$15,848,463.46 | -$15,942,828.29 |
| $4,262,561,283.40 |
| $4,994,412,918.01 |
| $5,761,557,240.51 |